NasdaqGM - Delayed Quote • USD
Theravance Biopharma, Inc. (TBPH)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:05 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 4 | 4 | 4 | 4 |
Avg. Estimate | -0.25 | -0.21 | -0.68 | -0.4 |
Low Estimate | -0.4 | -0.28 | -0.96 | -0.75 |
High Estimate | -0.16 | -0.18 | -0.3 | 0.32 |
Year Ago EPS | -0.35 | -0.28 | -1 | -0.68 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 4 | 4 | 4 | 4 |
Avg. Estimate | 13.96M | 15.6M | 71.1M | 83.2M |
Low Estimate | 11.1M | 14.7M | 61.4M | 73.7M |
High Estimate | 15.75M | 17.18M | 87.5M | 96.55M |
Year Ago Sales | 13.84M | 13.75M | 57.42M | 71.1M |
Sales Growth (year/est) | 0.90% | 13.50% | 23.80% | 17.00% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.26 | -0.21 | -0.21 | -0.15 |
EPS Actual | -0.35 | -0.28 | -0.17 | -0.17 |
Difference | -0.09 | -0.07 | 0.04 | -0.02 |
Surprise % | -34.60% | -33.30% | 19.00% | -13.30% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.25 | -0.21 | -0.68 | -0.4 |
7 Days Ago | -0.25 | -0.21 | -0.68 | -0.4 |
30 Days Ago | -0.25 | -0.22 | -0.64 | -0.32 |
60 Days Ago | -0.25 | -0.23 | -0.61 | -0.2 |
90 Days Ago | -0.25 | -0.23 | -0.61 | -0.2 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | TBPH | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 28.60% | -- | -- | 6.50% |
Next Qtr. | 25.00% | -- | -- | 12.00% |
Current Year | 32.00% | -- | -- | 5.30% |
Next Year | 41.20% | -- | -- | 13.10% |
Next 5 Years (per annum) | 54.10% | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Initiated | BTIG: Buy | 4/12/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2023 |
Maintains | HC Wainwright & Co.: Buy | 5/9/2023 |
Reiterates | HC Wainwright & Co.: Buy | 2/28/2023 |
Maintains | SVB Leerink: Outperform | 11/17/2022 |
Maintains | HC Wainwright & Co.: Buy | 11/8/2022 |
Related Tickers
SYBX Synlogic, Inc.
1.8700
-1.06%
PMVP PMV Pharmaceuticals, Inc.
1.7500
+2.34%
PRTC PureTech Health plc
28.50
+2.24%
KALV KalVista Pharmaceuticals, Inc.
10.78
+2.76%
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
SPRO Spero Therapeutics, Inc.
1.4600
+2.10%
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
ZA8.BE Zymeworks Inc
7.70
+1.32%
RPHM Reneo Pharmaceuticals, Inc.
1.6700
+1.21%
XNCR Xencor, Inc.
19.98
+3.90%